SCHEMBL6830952

SCHEMBL6830952

CCOC(=O)C=C(c1ccccc1)c1cccc(NS(=O)(=O)c2ccc(OC)cc2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TCF4 P15884 2/20 0.61
CTNNB1 P35222 2/20 0.61
CYP19A1 P11511 1/20 0.55
HTT P42858 4/20 0.53
THRB P10828 1/20 0.53
ALDH1A1 P00352 5/20 0.53
LMNA P02545 4/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
HPGD P15428 3/20 0.53
PKM P14618 1/20 0.53
MAPT P10636 4/20 0.52
GAA P10253 2/20 0.52
MAPK1 P28482 2/20 0.52
ALOX15 P16050 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
KDM4E B2RXH2 1/20 0.52
TP53 P04637 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6830949 1.00 TCF4 (0.61) TCF4CTNNB1CYP19A1HTTTHRB
SCHEMBL6834369 0.97 TCF4 (0.65) TCF4CTNNB1CYP19A1HTTTHRB
SCHEMBL6833574 0.89 TCF4 (0.55) TCF4CTNNB1CYP19A1HTTTHRB
SCHEMBL6836006 0.89 TCF4 (0.55) TCF4CTNNB1CYP19A1HTTTHRB
SCHEMBL6927343 0.89 TCF4 (0.55) TCF4CTNNB1CYP19A1HTTTHRB
SCHEMBL6836008 0.89 TCF4 (0.55) TCF4CTNNB1CYP19A1HTTTHRB
SCHEMBL6836003 0.89 TCF4 (0.55) TCF4CTNNB1CYP19A1HTTTHRB
SCHEMBL6833462 0.87 TCF4 (0.69) TCF4CTNNB1CYP19A1HTTTHRB
SCHEMBL6833460 0.87 TCF4 (0.69) TCF4CTNNB1CYP19A1HTTTHRB
SCHEMBL6834499 0.85 TCF4 (0.72) TCF4CTNNB1CYP19A1HTTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040029928-A1 Novel propenohydroxamic acid derivatives WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2004-02-12 US disclosed
EP-1314721-A1 NOVEL PROPENOHYDROXAMIC ACID DERIVATIVES WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2003-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029928-A1 Novel propenohydroxamic acid derivatives TNF, SI, HDGF TCF4 2045/4885CTNNB1 1993/4885CYP19A1 856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.